Stock Events

Stock Events

Aclaris Therapeutics 

$6.35
59
+$0.19+3.08% 08:29 Today

Statistics

Day High
6.18
Day Low
6.15
52W High
6.6
52W Low
1.74
Volume
98,980
Avg. Volume
-
Mkt Cap
906.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

11NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.01
-0.71
-0.42
-0.12
Expected EPS
-0.16622
Actual EPS
N/A

Financials

-829.58%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.83MRevenue
-64.92MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 16.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACRS. It's not an investment recommendation.
Tesla
9
TSLA
NVIDIA
9
NVDA
Alphabet
8
GOOGL
AMD
8
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals competes in the dermatology space, particularly in treatments for conditions like atopic dermatitis, which overlaps with Aclaris's focus areas.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie, through its acquisition of Allergan, has a strong presence in dermatology and aesthetics, directly competing with Aclaris's pipeline of skin condition treatments.
AMGEN
AMGN
Mkt Cap237.52B
Amgen has a portfolio that includes treatments for psoriasis and other skin conditions, making it a direct competitor to Aclaris in the dermatological treatment market.
Journey Medical
DERM
Mkt Cap218.74M
Journey Medical Corporation (formerly Dermira) focuses on dermatological solutions, including therapies for skin conditions that Aclaris also targets.
Novartis
NVS
Mkt Cap301.95B
Novartis offers products for skin conditions such as psoriasis, directly competing with Aclaris's dermatology-focused pipeline.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline has a broad portfolio that includes treatments for skin diseases, positioning it as a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap651.25B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops treatments for psoriasis and other skin conditions, competing with Aclaris.
Lilly(Eli) &
LLY
Mkt Cap1.12T
Eli Lilly has entered the dermatology market with treatments for conditions like atopic dermatitis, making it a competitor to Aclaris.
Merck
MRK
Mkt Cap376.37B
Merck & Co. has a diverse pharmaceutical portfolio that, while not focused on dermatology, includes treatments that could compete with Aclaris's products in broader therapeutic areas.

About

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Show more...
CEO
Neal S. Walker
Employees
73
Country
United States
ISIN
US00461U1051
WKN
000A1412H

Listings

STU
DE
8AT.STU
F
DE
8AT.F
MU
DE
8AT.MU
LSE
GB
0H8T.LSE

0 Comments

Share your thoughts

FAQ

What is Aclaris Therapeutics stock price today?▼
The current price of ACRS is $6.35 USD — it has increased by +3.08% in the past 24 hours. Watch Aclaris Therapeutics stock price performance more closely on the chart.
What is Aclaris Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Aclaris Therapeutics stocks are traded under the ticker ACRS.
Is Aclaris Therapeutics stock price growing?▼
ACRS stock has fallen by -3.9% compared to the previous week, the month change is a +15.57% rise, over the last year Aclaris Therapeutics has showed a +234.78% increase.
What is Aclaris Therapeutics market cap?▼
Today Aclaris Therapeutics has the market capitalization of 906.75M
When is the next Aclaris Therapeutics earnings date?▼
Aclaris Therapeutics is going to release the next earnings report on November 11, 2026.
What were Aclaris Therapeutics earnings last quarter?▼
ACRS earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.16 USD resulting in a +6.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aclaris Therapeutics revenue for the last year?▼
Aclaris Therapeutics revenue for the last year amounts to 7.83M USD.
What is Aclaris Therapeutics net income for the last year?▼
ACRS net income for the last year is -64.92M USD.
How many employees does Aclaris Therapeutics have?▼
As of August 28, 2026, the company has 73 employees.
In which sector is Aclaris Therapeutics located?▼
Aclaris Therapeutics operates in the Health & Wellness sector.
When did Aclaris Therapeutics complete a stock split?▼
The last stock split for Aclaris Therapeutics was on November 09, 2015 with a ratio of 6:5.
Where is Aclaris Therapeutics headquartered?▼
Aclaris Therapeutics is headquartered in WAYNE, United States.